Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pharmazie ; 65(12): 867-70, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21284254

RESUMEN

Tamoxifen (TAM), the clinical choice for the antiestrogen treatment of advanced or metastatic breast cancer, was formulated in nanoparticulate carrier systems in the form of poly(lactide-co-glycolide) (PLGA), poly-epsilon-caprolactone (PCL) and chitosan (CS) nanoparticles. The PLGA and PCL nanoparticles were prepared by a nanoprecipitation technique whereas the CS nanoparticles were prepared by the ionic gelation method. Mean particle sizes were under 260 nm for PLGA and PCL nanoparticles and around 400 nm for CS nanoparticles. Polydispersity indices were less than 0.4 for all formulations. Zeta potential values were positive for TAM loaded nanoparticles because of the positive charge of the drug. Drug loading values were significantly higher for PCL nanoparticles when compared to PLGA and CS nanoparticles. All nanoparticle formulations exhibited controlled release properties. These results indicate that TAM loaded PLGA, PCL and CS nanoparticles may provide promising carrier systems for tumor targeting.


Asunto(s)
Antagonistas de Estrógenos/administración & dosificación , Tamoxifeno/administración & dosificación , Disponibilidad Biológica , Quitosano , Cromatografía Líquida de Alta Presión , Composición de Medicamentos , Sistemas de Liberación de Medicamentos , Electroquímica , Antagonistas de Estrógenos/química , Excipientes , Ácido Láctico , Microscopía Electrónica de Rastreo , Nanopartículas , Tamaño de la Partícula , Poliésteres , Ácido Poliglicólico , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Tamoxifeno/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA